Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DnaJ heat shock protein family member C1 (DNAJC1)
- Target
- DNAJC1
- Molecular classification
- Co-chaperone protein (Hsp40 family), Heat shock protein, Membrane protein, SANT/Myb domain containing protein, Other (binds chaperone BiP/GRP78)
01
Overview
DnaJ heat shock protein family member C1 (DNAJC1) is a multifunctional co-chaperone of the Hsp40 (DnaJ) family, primarily associated with the endoplasmic reticulum membrane. It modulates protein folding by binding the molecular chaperone BiP/GRP78, contains two SANT domains for chromatin and serpin interactions, and participates in the unfolded protein response, cellular proliferation, and stress adaptation. Aberrant regulation or expression of DNAJC1 has been implicated in cancer progression, metabolic homeostasis disturbances, and myopathies. DNAJC1 also interacts with alpha 1-antichymotrypsin and inter-alpha trypsin inhibitor heavy chain 4
- Other names
- DNAJC1DnaJ homolog subfamily C member 1DNAJL1ERdj1MTJ1HTJ1DnaJ (Hsp40) homolog, subfamily C, member 1
02
Mechanism of action
Mechanisms for targeting DNAJC1 would likely involve modulation of protein folding, cellular stress adaptation, and chaperone interactions. Drug mechanisms may overlap with those targeting the unfolded protein response and co-chaperone networks.
03
Biological functions
Protein folding/quality controlChaperone bindingATPase activator activityChromatin bindingCellular stress response (unfolded protein response)Regulation of metabolic homeostasisCellular proliferation
04
Disease associations
Cancer (including glioblastoma progression; upregulation in leukemia)Metabolic disease (correlated with adiposity, body fat mass, insulin resistance)Muscle atrophy (associated with recovery of denervated muscle)PyometritisOther (potential implications in feed efficiency and gastrointestinal metabolism)
05
Safety considerations
Potential therapeutic challenges with heat shock protein targeting include cellular stress adaptation, off-target effects on protein homeostasis, and impacts on metabolic and proliferative pathways.
06
Interacting drugs
No direct drugs listed in the references; perturbations in DNAJC1 gene expression observed in chemical screening studies and cancer models. Interacts with molecular chaperone BiP/GRP78, which is targeted in oncology; DNAJC1-related pathways may indirectly be influenced by heat shock protein inhibitors.
07
Biomarkers
DNAJC1 methylation status and gene expression have been suggested as biomarkers for adiposity, body fat mass, insulin resistance, and cancer risk loci. No current clinical biomarkers used for patient selection or therapy monitoring are directly listed.
Beyond the preview
Go deeper on DnaJ heat shock protein family member C1 (DNAJC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DnaJ heat shock protein family member C1 (DNAJC1).